Vanguard Group Inc. Has $128.25 Million Holdings in Artivion, Inc. $AORT

Vanguard Group Inc. boosted its holdings in shares of Artivion, Inc. (NYSE:AORT) by 8.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,029,059 shares of the company’s stock after acquiring an additional 232,424 shares during the period. Vanguard Group Inc. owned approximately 0.06% of Artivion worth $128,250,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AORT. JPMorgan Chase & Co. raised its position in shares of Artivion by 338.2% during the third quarter. JPMorgan Chase & Co. now owns 122,199 shares of the company’s stock worth $5,174,000 after purchasing an additional 94,312 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Artivion by 6.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock valued at $349,000 after purchasing an additional 477 shares during the period. Public Sector Pension Investment Board increased its stake in Artivion by 23.7% during the 3rd quarter. Public Sector Pension Investment Board now owns 161,970 shares of the company’s stock worth $6,858,000 after purchasing an additional 30,989 shares in the last quarter. Illinois Municipal Retirement Fund raised its holdings in Artivion by 4.0% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 21,535 shares of the company’s stock worth $912,000 after buying an additional 829 shares during the period. Finally, Rhumbline Advisers raised its holdings in Artivion by 3.0% during the 3rd quarter. Rhumbline Advisers now owns 114,134 shares of the company’s stock worth $4,832,000 after buying an additional 3,272 shares during the period. 86.37% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts maintain a constructive view — the consensus rating reported is “Moderate Buy,” and several firms have reiterated buy/outperform ratings and mid‑to‑high price targets, which can support demand for AORT shares. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present virtually at the Oppenheimer Healthcare MedTech & Services Conference (fireside chat), giving the company a chance to update guidance, product progress or commercialization milestones — an event that often attracts buy‑side attention. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Institutional investors have been adding to positions (Invesco, Summit Partners, Goldman Sachs, Two Sigma among those increasing exposure), which can provide steady bid support and signal confidence from larger, professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates (Feb. 12), showing top‑line growth; this underpins the bull case but may already be priced in given prior analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold shares on March 2 (CEO James Mackin sold ~14.9k shares; EVP Lance Berry and several SVPs also sold), a cluster of sales that markets often interpret as a negative signal even though insiders retain large holdings. See the SEC Form 4 for details. SEC Form 4 – Mackin

Analyst Ratings Changes

Several brokerages have recently issued reports on AORT. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Oppenheimer reiterated an “outperform” rating and set a $50.00 target price on shares of Artivion in a report on Friday, November 7th. Needham & Company LLC restated a “buy” rating and issued a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Citizens Jmp upped their price objective on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Finally, Canaccord Genuity Group decreased their price objective on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $48.97.

Artivion Price Performance

NYSE:AORT opened at $38.56 on Wednesday. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.25. The company has a market cap of $1.85 billion, a P/E ratio of 192.81 and a beta of 1.60. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The stock’s 50-day simple moving average is $41.59 and its 200 day simple moving average is $42.95.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The firm’s quarterly revenue was up 19.2% on a year-over-year basis. As a group, sell-side analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Insider Buying and Selling at Artivion

In other news, CAO Amy Horton sold 4,572 shares of Artivion stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $44.42, for a total value of $203,088.24. Following the completion of the transaction, the chief accounting officer owned 130,058 shares of the company’s stock, valued at $5,777,176.36. This trade represents a 3.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO James P. Mackin sold 20,962 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $37.59, for a total transaction of $787,961.58. Following the transaction, the chief executive officer owned 780,031 shares in the company, valued at $29,321,365.29. This represents a 2.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 92,984 shares of company stock valued at $3,492,115 in the last 90 days. Company insiders own 8.10% of the company’s stock.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.